HCV: direct-acting antivirals halve risk for DM

  • Butt AA & al.
  • Clin Infect Dis
  • 12 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • HCV treatment with direct-acting antivirals (DAAs) is associated with a 47% reduced risk for subsequent diabetes mellitus (DM).

Why this matters

  • Magnitude of benefit is greater among patients with more advanced liver fibrosis/cirrhosis.

Study design

  • ERCHIVES data for 242,680 HCV-infected US Veterans; 2% received peginterferon-ribavirin (PEG/RBV) and 8.8% were treated with DAAs.
  • Treated and nontreated patients were matched by propensity score.
  • Primary outcome: incident diabetes >12 weeks postbaseline.
  • Funding: Gilead Sciences.  

Key results

  • Diabetes incidence was significantly lower in treated vs untreated patients (15.4 vs 20.6 per 1000 person-years [PY]; P<.0001>
  • Effect was driven by DAAs (9.89 vs 20.6 per 1000 PY; P<.0001 not vs per py p=".39).</li">
  • 78.8% achieved sustained virologic response at 12 weeks posttherapy (SVR12).
  • Among treated patients, diabetes rate was lower with SVR12 than without (13.3 vs 19.2 per 1000 PY; P<.0001>
  • Rate reduction benefit of treatment rose with disease severity. Absolute difference per 1000 PY:
    • 2.9 for fibrosis-4 index (FIB-4)
    • 5.7 for 1.26
    • 9.8 for FIB-4 >3.25.
  • DAA therapy (HR=0.53; 95% CI, 0.46-0.63) and SVR12 (HR=0.81; 95% CI, 0.70-0.93) predicted reduced risk for diabetes; PEG/RBV did not.
  • Diabetes-free survival was significantly longer with DAAs vs PEG/RBV and no treatment (P<.001>

Limitations

  • Retrospective design; predominantly male population.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit